未知生产厂商
RAV12 is investigated for use/treatment in solid tumors. RAV12 is a solid. RAV12 is a chimeric antibody that recognizes RAAG12, an N-linked carbohydrate antigen found on gastric, colon, pancreatic, prostate, ovarian, breast, and kidney cancer cells.
RAV12 is investigated for use/treatment in solid tumors. RAV12 is a solid. RAV12 is a chimeric antibody that recognizes RAAG12, an N-linked carbohydrate antigen found on gastric, colon, pancreatic, prostate, ovarian, breast, and kidney cancer cells.
RAV12 is a high affinity IgG1 chimeric antibody. RAAG12, the antigen target of RAV12 is a carbohydrate moiety whose expression is limited to primates. The structure of the RAV12 epitope is Galß 1-3GlcNacß 1-3Gal. Multiple RAV12 binding sites exist per sugar side-chain resulting in a very high apparent affinity and a nearly unmeasurable dissociation rate. Adenocarcinomas arising in breast, endometrial, ovarian, lung and prostate, display the RAA12 antigen to varying degrees. RAAG12 expression in normal tissues is generally limited to the apical membranes of certain epithelia of the GI track and the hepatobiliary system. Preclinical in vitro and in vivo experiments have suggested that RAV12 may have several anti-tumor activities, including direct cytotoxicity by a mechanism termed oncosis, antibody-dependent cellular cytotoxicity, complement mediated cytotoxicity, and alterations of cell survivability through down regulation of growth factor receptors. Oncosis is a form of cell death, distinct from apoptosis, that is characterized by loss of membrane integrity, followed by cell and organellar swelling, and death.
Investigated for use/treatment in solid tumors.
每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。
未检索到以该名称命名的专利
专利文献通常使用化学名或研发代号指代药物，而非通用名；且专利申请在提交约 18 个月后才公开，较新的药物可能尚未出现在这里。
